AC Immune stock climbs 7% on FDA fast track status for Alzheimer’s drug
by
Contributor since / Followers
Contributor since / Followers
4 months ago
IvelinRadkov
- AC Immune (NASDAQ:ACIU) stock rose 7% Wednesday following news that the FDA has granted Fast Track designation to its drug candidate ACI-35.030, also known as JNJ-2056, for the treatment of Alzheimer’s disease.
- The drug, an immunotherapy that targets a pathological form of the Tau protein, is being developed by partner Johnson & Johnson’s (NYSE:JNJ) Janssen unit.
- Janssen recently initiated a Phase 2b study of the drug for the treatment of Alzheimer’s in patients who haven’t yet shown symptoms. The study is evaluating whether the drug can help prevent or delay symptoms of the disease, such as cognitive impairment, according to a statement.